Sensipar, Mimpara (cinacalcet) is a small molecule pharmaceutical. Cinacalcet was first approved as Sensipar on 2004-03-08. It is used to treat parathyroid neoplasms, primary hyperparathyroidism, and secondary hyperparathyroidism in the USA. It has been approved in Europe to treat hypercalcemia, hyperparathyroidism, parathyroid neoplasms, and secondary hyperparathyroidism. The pharmaceutical is active against extracellular calcium-sensing receptor. In addition, it is known to target metabotropic glutamate receptor 5. Sensipar's patent is valid until 2026-09-22 (FDA).
|Indication||hypercalcemia, hyperparathyroidism, parathyroid neoplasms, primary hyperparathyroidism, secondary hyperparathyroidism|
|Drug Class||Calcium receptor agonists|